GLP1减重宝典·2025-05-24 08:16Core Viewpoint - The U.S. federal government has officially terminated the sale of compounded non-branded weight loss and diabetes medications, impacting patients reliant on these drugs for access to treatment [1][3]. Group 1: Regulatory Changes - The FDA has resolved the supply shortage of widely used GLP-1 medications, including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) [1][4]. - The FDA no longer permits the production or sale of compounded formulations of these drugs without agency approval, which were typically produced by small pharmacies during shortages [1][3]. Group 2: Patient Impact - Compounded semaglutide was a cheaper alternative for many patients, with Olympia Pharmaceuticals providing medication to over 70,000 patients weekly [3]. - Patients like Michelle Pierce from Texas express concern over losing access to affordable medication, highlighting the financial burden of out-of-pocket costs [3][10]. Group 3: Safety Concerns - Medical professionals have raised safety concerns regarding compounded GLP-1 medications, citing lack of reliable regulation and unknowns about composition and interactions with other drugs [3][6]. - The production and sale of unapproved compounded formulations are deemed illegal and potentially hazardous to patient safety [6]. Group 4: Supply and Insurance Issues - Manufacturers like Novo Nordisk express confidence in their production capabilities to meet current and anticipated demand [4][5]. - Despite improvements in supply, insurance coverage for these medications has worsened, complicating access for patients [7].